ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KYNB / forecast
ACTU (35) AKTX (37) COCP (36) MCRB (40) ⌘ Pro Terminal →

Kyntra Bio Inc. (KYNB) 12-Month Stock Forecast & Price Target Cone

$4.57 -1.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.55

Kyntra Bio Inc. (KYNB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $18.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KYNB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kyntra Bio Inc. (NASDAQ: KYNB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.57 (-1.72% 1D, market cap $18.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, KYNB ranks #735 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KYNB compare to ACTU and AKTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KYNB?
▼

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.55 (-0.50%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (3)SEC (12)Macro (6)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-11.6% Base Target
$12 Bull$4 Base$3 Bear
📬 FREE KYNB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KYNB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY KYNB SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$5.87-10.1% Next Q
Q2 (-2Q)
37
Grade E$5.28-14.8% Next Q
Q3 (-1Q)
35
Grade E$4.50+1.6% Next Q
Current
32
Grade E$4.57-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KYNB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KYNB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.56) and Max Pain ($4.80) forces dealer call-delta covering toward $11.96.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KYNB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KYNB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KYNB Position Size: $10,000

Shares at $4.57: 2188.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.15
$6,893
$-3,107 (-31.1%)
12M Consensus BaseTarget $4.04
$8,840
$-1,160 (-11.6%)
12M Bull Case BreakoutTarget $11.96
$26,171
+$16,171 (+161.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1169%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYNB)

  • ✓Walkthrough of KYNB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KYNB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.53%📐 HORIZONTAL RANGE
2026-11-03O $4.65H $4.65L $4.57C $4.57VOL 24.4K
RES: $9.18SUP: $4.13SMA50: $6.56SMA200: $7.06
$9.27$7.93$6.59$5.25$3.90RES $9.18SUP $4.13$4.572026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYNB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYNB Butterfly Map → + Track KYNB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -78.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KYNB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYNB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KYNB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYNB)

Health Care Rank #735 of 1015 ⚔️ ACTU vs KYNB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KYNB vs. ACTU, AKTX, COCP, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kyntra Bio Inc. (KYNB) ranks #735 by composite RQD confidence (32/100, grade E) and #834 by equity capitalization ($18.5M). Within this direct 5-issuer industry benchmark cohort, KYNB leads on earnings valuation at N/A trailing P/E, while KYNB leads on capital efficiency and profitability with -35.0% ROIC and 91.4% gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with KYNB at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KYNB ACTIVE
Kyntra Bio Inc.
E 32/100 — 91.4% -35.0% -1.72% $18.5M Benchmark Subject
ACTU
Actuate Therapeutics Inc.
D- 35/100 — — -35.0% -9.68% $18.4M /actu-vs-kynb →
AKTX
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% +3.00% $18.8M /aktx-vs-kynb →
COCP
Cocrystal Pharma Inc.
D- 36/100 — — -35.0% +1.53% $19.2M /cocp-vs-kynb →
MCRB
Seres Therapeutics Inc.
D- 40/100 — — -35.0% -9.23% $17.8M /mcrb-vs-kynb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921299 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported GAAP revenue of $6.4M (-78.3% vs. FY2024 revenue of $29.6M , and -86.2% cumulative change since FY2023) , GAAP net income of $183.5M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+96.5% YoY). On the balance sheet, KYNB closed FY2025 with $119.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.4M $183.5M -$4.8M -$4.8M $119.6M —
FY2024 (FY) 2024-12-31 $29.6M -$47.6M -$138.0M -$138.3M $214.5M —
FY2023 (FY) 2023-12-31 $46.8M -$284.2M -$315.0M -$315.0M — —

3. KYNB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kyntra Bio Inc. (NASDAQ: KYNB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.57 (-1.72% 1D, market cap $18.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, KYNB ranks #735 in composite RQD confidence.

How does KYNB compare to ACTU and AKTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KYNB?

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KYNB trading relative to its 50-day, 200-day, and 52-week technical levels?

KYNB last traded at $4.57 (-1.72% on volume of 24,430 shares), positioning the stock -30.34% below its 50-day simple moving average ($6.56) and -35.27% below its 200-day simple moving average ($7.06). Across its 52-week range of $4.32 to $11.39, KYNB sits at the 3.5% percentile with a 14-day RSI of 28.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.00 to $5.14).

Direct Sub-Reports: KYNB RQD Cockpit KYNB 12M Forecast KYNB Earnings & Move KYNB Dividends & DRIP KYNB Insiders & 13F KYNB Whale Options KYNB Profit Sankey KYNB News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

KYNB — Kyntra Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kyntra Bio Inc. (KYNB) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.57 (-1.72% 1D, market capitalization $18.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 91.4%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kyntra Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 91.4%, indicating a high gross margin profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported $6.4M in annual revenue (up from $29.6M in FY2024, -78.3% YoY) and $183.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.8M revenue, -$284.2M net income) through FY2025, KYNB scaled operating cash flow to -$4.8M and free cash flow to -$4.8M, backed by $119.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.32 – $11.39 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation mappings are therefore — A prospective investor should note that any second-order ripple analysis cannot be derived from the provided graph; the most material second-order risk visible in the sources is the listing-status question, which could affect liquidity and institutional eligibility.

  • Key Question #1: Can KYNB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.4M and free cash flow of -$4.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KYNB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KYNB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kyntra Bio Inc. (KYNB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KYNB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KYNB Bull vs. Bear Conversation Board — What's Your Call at $4.57?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KYNB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KYNB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $5.39 (+17.9%)
📌 Pinned Debate

Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.

Here is why I am bullish on KYNB here at $4.57: Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.. Compare KYNB's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.34 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — KYNB's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.56 (-22.1%)
Spot @ $4.57

Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.

I respect the product at Kyntra Bio Inc., but the stock at $4.57 is a different story. Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.. FCF yield is 0.0% and RQD sits at 32/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%